Cargando…
Physicochemical properties of SARS‐CoV‐2 for drug targeting, virus inactivation and attenuation, vaccine formulation and quality control
The material properties of the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) and its proteins are discussed. We review the viral structure, size, rigidity, lipophilicity, isoelectric point, buoyant density and centrifugation conditions, stability against pH, temperature, UV light, gam...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7283733/ https://www.ncbi.nlm.nih.gov/pubmed/32469436 http://dx.doi.org/10.1002/elps.202000121 |
_version_ | 1783544343629398016 |
---|---|
author | Scheller, Christin Krebs, Finja Minkner, Robert Astner, Isabel Gil‐Moles, Maria Wätzig, Hermann |
author_facet | Scheller, Christin Krebs, Finja Minkner, Robert Astner, Isabel Gil‐Moles, Maria Wätzig, Hermann |
author_sort | Scheller, Christin |
collection | PubMed |
description | The material properties of the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) and its proteins are discussed. We review the viral structure, size, rigidity, lipophilicity, isoelectric point, buoyant density and centrifugation conditions, stability against pH, temperature, UV light, gamma radiation, and susceptibility to various chemical agents including solvents and detergents. Possible inactivation, downstream, and formulation conditions are given including suitable buffers and some first ideas for quality‐control methods. This information supports vaccine development and discussion with competent authorities during vaccine approval and is certainly related to drug‐targeting strategies and hygienics. Several instructive tables are given, including the pI and grand average of hydropathicity (GRAVY) of SARS‐CoV‐1 and ‐2 proteins in comparison. SARS‐CoV‐1 and SARS‐CoV‐2 are similar in many regards, so information can often be derived. Both are unusually stable, but sensitive at their lipophilic membranes. However, since seemingly small differences can have strong effects, for example, on immunologically relevant epitope settings, unevaluated knowledge transfer from SARS‐CoV‐1 to SARS‐CoV‐2 cannot be advised. Published knowledge regarding downstream processes, formulations and quality assuring methods is, as yet, limited. However, standard approaches employed for other viruses and vaccines seem to be feasible including virus inactivation, centrifugation conditions, and the use of adjuvants. |
format | Online Article Text |
id | pubmed-7283733 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-72837332020-06-10 Physicochemical properties of SARS‐CoV‐2 for drug targeting, virus inactivation and attenuation, vaccine formulation and quality control Scheller, Christin Krebs, Finja Minkner, Robert Astner, Isabel Gil‐Moles, Maria Wätzig, Hermann Electrophoresis Fast Track The material properties of the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) and its proteins are discussed. We review the viral structure, size, rigidity, lipophilicity, isoelectric point, buoyant density and centrifugation conditions, stability against pH, temperature, UV light, gamma radiation, and susceptibility to various chemical agents including solvents and detergents. Possible inactivation, downstream, and formulation conditions are given including suitable buffers and some first ideas for quality‐control methods. This information supports vaccine development and discussion with competent authorities during vaccine approval and is certainly related to drug‐targeting strategies and hygienics. Several instructive tables are given, including the pI and grand average of hydropathicity (GRAVY) of SARS‐CoV‐1 and ‐2 proteins in comparison. SARS‐CoV‐1 and SARS‐CoV‐2 are similar in many regards, so information can often be derived. Both are unusually stable, but sensitive at their lipophilic membranes. However, since seemingly small differences can have strong effects, for example, on immunologically relevant epitope settings, unevaluated knowledge transfer from SARS‐CoV‐1 to SARS‐CoV‐2 cannot be advised. Published knowledge regarding downstream processes, formulations and quality assuring methods is, as yet, limited. However, standard approaches employed for other viruses and vaccines seem to be feasible including virus inactivation, centrifugation conditions, and the use of adjuvants. John Wiley and Sons Inc. 2020-06-08 2020-07 /pmc/articles/PMC7283733/ /pubmed/32469436 http://dx.doi.org/10.1002/elps.202000121 Text en © 2020 The Authors. Electrophoresis published by Wiley‐VCH Verlag GmbH & Co. KGaA https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Fast Track Scheller, Christin Krebs, Finja Minkner, Robert Astner, Isabel Gil‐Moles, Maria Wätzig, Hermann Physicochemical properties of SARS‐CoV‐2 for drug targeting, virus inactivation and attenuation, vaccine formulation and quality control |
title | Physicochemical properties of SARS‐CoV‐2 for drug targeting, virus inactivation and attenuation, vaccine formulation and quality control |
title_full | Physicochemical properties of SARS‐CoV‐2 for drug targeting, virus inactivation and attenuation, vaccine formulation and quality control |
title_fullStr | Physicochemical properties of SARS‐CoV‐2 for drug targeting, virus inactivation and attenuation, vaccine formulation and quality control |
title_full_unstemmed | Physicochemical properties of SARS‐CoV‐2 for drug targeting, virus inactivation and attenuation, vaccine formulation and quality control |
title_short | Physicochemical properties of SARS‐CoV‐2 for drug targeting, virus inactivation and attenuation, vaccine formulation and quality control |
title_sort | physicochemical properties of sars‐cov‐2 for drug targeting, virus inactivation and attenuation, vaccine formulation and quality control |
topic | Fast Track |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7283733/ https://www.ncbi.nlm.nih.gov/pubmed/32469436 http://dx.doi.org/10.1002/elps.202000121 |
work_keys_str_mv | AT schellerchristin physicochemicalpropertiesofsarscov2fordrugtargetingvirusinactivationandattenuationvaccineformulationandqualitycontrol AT krebsfinja physicochemicalpropertiesofsarscov2fordrugtargetingvirusinactivationandattenuationvaccineformulationandqualitycontrol AT minknerrobert physicochemicalpropertiesofsarscov2fordrugtargetingvirusinactivationandattenuationvaccineformulationandqualitycontrol AT astnerisabel physicochemicalpropertiesofsarscov2fordrugtargetingvirusinactivationandattenuationvaccineformulationandqualitycontrol AT gilmolesmaria physicochemicalpropertiesofsarscov2fordrugtargetingvirusinactivationandattenuationvaccineformulationandqualitycontrol AT watzighermann physicochemicalpropertiesofsarscov2fordrugtargetingvirusinactivationandattenuationvaccineformulationandqualitycontrol |